Meningococcal meningitis in Spain in the Horizon 2030: A position paper
Authors:
- Fernando Moraga-LlopFMFernando Moraga-Llop
- Elena AndradasEAElena Andradas
- Luis Carlos Blesa-BavieraLBLuis Carlos Blesa-Baviera
- Rafael CantónRCRafael Cantón
- Juan González del CastilloJCJuan González del Castillo
- Federico Martinón-TorresFederico Martinón-Torres
- Elena MoyaEMElena Moya
- Antoni TrillaATAntoni Trilla
- Julio VazquezJVJulio Vazquez
- Rodolfo Javier VillenaRVRodolfo Javier Villena
- Julián Ruiz-GalianaJRJulián Ruiz-Galiana
- Pilar De Lucas RamosPRPilar De Lucas Ramos
Open Access
- 22 March 2024
- journal article
- research article
- Published by Sociedad Espanola de Quimioterapia in Revista Española de Quimioterapia
- Vol. 37 (4) , 285-298
Abstract
Meningococcal meningitis (MM) and invasive meningococcal disease remain a major public health problem that generates enormous public alarm. It is caused by Neisseria meningitidis, a Gram-negative diplococcus with an enormous capacity for acute and rapidly progressive disease, both episodic and epidemic in nature, with early diagnosis and treatment playing a major role. It occurs at any age, but is most common in children under 5 years of age followed by adolescents. Although most cases occur in healthy people, the incidence is higher in certain risk groups. Despite advances in reducing the incidence, it is estimated that in 2017 there were around 5 million new cases of MM worldwide, causing approximately 290,000 deaths and a cumulative loss of about 20,000,000 years of healthy life. In Spain, in the 2021/22 season, 108 microbiologically confirmed cases of MM were reported, corresponding to an incidence rate of 0.23 cases per 100,000 inhabitants. This is a curable and, above all, vaccine-preventable disease, for which the World Health Organisation has drawn up a roadmap with the aim of reducing mortality and sequelae by 2030. For all these reasons, the Illustrious Official College of Physicians of Madrid (ICOMEM) and the Medical Associations of 8 other provinces of Spain, have prepared this opinion document on the situation of MM in Spain and the resources and preparation for the fight against it in our country. The COVID-19 and Emerging Pathogens Committee of ICOMEM has invited experts in the field to participate in the elaboration of this document.Keywords
This publication has 32 references indexed in Scilit:
- Effectiveness of Meningococcal Vaccines at Reducing Invasive Meningococcal Disease and Pharyngeal Neisseria meningitidis Carriage: A Systematic Review and Meta-analysisClinical Infectious Diseases, 2020
- First Real-world Evidence of Meningococcal Group B Vaccine, 4CMenB, Protection Against Meningococcal Group W Disease: Prospective Enhanced National Surveillance, EnglandClinical Infectious Diseases, 2020
- Meningococcal B Vaccine and Meningococcal Carriage in Adolescents in AustraliaNew England Journal of Medicine, 2020
- Neisseria meningitidis: using genomics to understand diversity, evolution and pathogenesisNature Reviews Microbiology, 2019
- An Overview of Neisseria meningitidis2019
- Antibióticos y el factor tiempo en la infección en urgenciasEnfermedades Infecciosas y Microbiología Clínica, 2013
- Vaccine offers meningitis hopeNature, 2010
- Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programsExpert Review of Vaccines, 2009
- An Ill Wind, Bringing MeningitisScience, 2008
- Community-Acquired Bacterial Meningitis in AdultsNew England Journal of Medicine, 2006